Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan

详细信息    查看全文

• 作者：Takuya Matsunaga (1) (4)
  Kiyoshi Yamashita (2)
  Yoko Kubuki (1)
  Takanori Toyama (3)
  Osamu Imataki (4)
  Kouichi Maeda (5)
  Noriaki Kawano (2)
  Seiichi Satou (6)
  Hiroshi Kawano (7)
  Junzo Ishizaki (8)
  Shuro Yoshida (2)
  Takuro Kameda (1)
  Tadashi Sasaki (3)
  Masaaki Sekine (1)
  Ayako Kamiunten (1)
  Yasuhiro Taniguchi (1)
  Tomonori Hidaka (1)
  Keiko Katayose (1)
  Haruko K-Shimoda (1)
  Kotaro Shide (1)
  Shojiro Yamamoto (1)
  Hiroshi Moritake (9)
  Hiroyuki Nunoi (9)
  Shigeyoshi Makino (2)
  Akira Kitanaka (1)
  Hitoshi Matsuoka (7)
  Kazuya Shimoda (1)
  
• 关键词：Acute myeloid leukemia (AML) ; Population ; based study ; Clinical practice
• 刊名：International Journal of Hematology
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：96
• 期：3
• 页码：342-349
• 全文大小：279KB
• 参考文献：1. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute leukemia: the JALSG AML201 Study. Blood. 2011;117:2358-5. CrossRef
  2. Burnett AK. The treatment of AML: current status and novel approaches. Hematology. 2005;10(Suppl 1):50-. CrossRef
  3. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65?years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-. CrossRef
  4. Mauritzson N, Johansson B, Albin M, Billstrom R, Ahlgren T, Mikoczy Z, et al. A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. Eur J Haematol. 1999;62:95-02. CrossRef
  5. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179-7. CrossRef
  6. Taylor PR, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor SJ. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. Leukemia. 1995;9:231-.
  7. Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009;9:252. CrossRef
  8. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91:1400-.
  9. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008;93:594-00. CrossRef
  10. Nakase K, Bradstock K, Sartor M, Gottlieb D, Byth K, Kita K, et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia. 2000;14:163-. CrossRef
  11. NCCN. Guideline. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Aug 28 2010.
  12. BCSH. Guidelines. http://www.bcshguidelines.com/guidelinesMENU.asp. Accessed Aug 28 2010.
  13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322-3.
  14. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-3.
  15. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-6. CrossRef
  16. Cox D. Logistic regression for binary response variables. London: Champman & Hall; 1989. p. 33-3.
  17. Grambsch PTT. Proportional hazard tests and diagnostic based on weighted residuals. Biometrika. 1994;81:515-6. CrossRef
  18. SEER. Cancer statistics review 1975-006. http://seer.cancer.gov. Accessed Aug 28 2010.
  19. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16:78-5.
  20. Sanz MA, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104:3490-. CrossRef
  21. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-. CrossRef
  22. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-0. CrossRef
  23. Moorman AV, Roman E, Willett EV, Dovey GJ, Cartwright RA, Morgan GJ. Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet Cytogenet. 2001;126:155-1. CrossRef
  24. Schoch C, Kern W, Krawitz P, Dugas M, Schnittger S, Haferlach T, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood. 2001;98:3500. CrossRef
  25. Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75?years of age with acute myeloid leukemia. Haematologica. 1998;83:126-1.
  26. Iwakiri R, Ohta M, Mikoshiba M, Tsutsumi H, Kumakawa T, Mori M. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases. Int J Hematol. 2002;75:45-0. CrossRef
  27. Erba HP. Prognositic factors in elderly patients with AML and the implications for treatment. In: American Society of Hematology Education Program Book; 2007. p. 420-28.
  28. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-3. CrossRef
  29. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385-00. CrossRef
  30. Sakamaki H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, et al. Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study. Int J Hematol. 2010;91:284-2. CrossRef
  31. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366-2
  
• 作者单位：Takuya Matsunaga (1) (4)
  Kiyoshi Yamashita (2)
  Yoko Kubuki (1)
  Takanori Toyama (3)
  Osamu Imataki (4)
  Kouichi Maeda (5)
  Noriaki Kawano (2)
  Seiichi Satou (6)
  Hiroshi Kawano (7)
  Junzo Ishizaki (8)
  Shuro Yoshida (2)
  Takuro Kameda (1)
  Tadashi Sasaki (3)
  Masaaki Sekine (1)
  Ayako Kamiunten (1)
  Yasuhiro Taniguchi (1)
  Tomonori Hidaka (1)
  Keiko Katayose (1)
  Haruko K-Shimoda (1)
  Kotaro Shide (1)
  Shojiro Yamamoto (1)
  Hiroshi Moritake (9)
  Hiroyuki Nunoi (9)
  Shigeyoshi Makino (2)
  Akira Kitanaka (1)
  Hitoshi Matsuoka (7)
  Kazuya Shimoda (1)
  
  1. Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan
  4. Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan
  2. Miyazaki Prefectural Miyazaki Hospital, Kitatakamatsu 5-30, Miyazaki, 880-8510, Japan
  3. Miyazaki Prefectural Nobeoka Hospital, Shinkouji 2-1-10, Nobeoka, 882-0835, Japan
  5. Miyakonojo National Hospital, Iwayoshi-cho 5033-1, Miyakonojo, 885-0014, Japan
  6. Fujimoto Hayasuzu Hospital, Hayasuzumachi 17-1, Miyakonojo, 885-0055, Japan
  7. Koga General Hospital, Sudaki 1749-1, Ikeuchi-cho, Miyazaki, 880-0041, Japan
  8. Miyazaki Prefectural Nichinan Hospital, Kiyama 1-19-5, Nichinan, 887-0013, Japan
  9. Division of Pediatrics, Department of Reproductive and Developmental Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan
  

文摘

We performed a retrospective population-based cohort study of acute myeloid leukemia (AML) in Miyazaki Prefecture, Japan. Over 6?years, we diagnosed 221 patients (211 adults and 10 children) with AML, indicating an incidence of AML in Miyazaki Prefecture of 3.2 per 100,000 per year. In 193 adult patients with non-acute promyelocytic leukemia (APL), the proportion of patients with myelodysplasia, unfavorable risk karyotypes, antecedent hematologic diseases, prior chemotherapy for other malignancies, and small proportion of blasts in the marrow was higher in patients ?5?years, and patients with poor performance status (PS) and higher WBC counts at diagnosis were more prevalent among patients ?5?years. One-third of the adult non-APL patients met the inclusion criteria usually applied in clinical trials: de novo AML, age ?4?years with PS 0- and no key organ dysfunction. The 5-year overall survival (OS) rate of adult non-APL patients was 21.1?% (patients ?4?years, 33.8?%; 65-4?years, 21.6?%; ?5?years, 0?%). Multivariate analysis revealed that French-American-British subtypes M0, M6, and M7, poor PS (3, 4), unfavorable risk karyotypes, and higher WBC counts at diagnosis were independent adverse prognostic factors associated with OS. This analysis provides real world data.